Tamoxifen was the first targeted therapy for breast cancer which was given to ER+ (estrogen receptor-positive) breast cancer patients to bind to estrogen receptor (ER) and antagonize the proliferative ability potentiated by binding of ER to growth hormone estrogen (10). This evidence concerns the gene GH1 and breast carcinoma.